These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

304 related items for PubMed ID: 24898642

  • 1. Cholinesterase inhibition in Alzheimer's disease: is specificity the answer?
    Macdonald IR, Rockwood K, Martin E, Darvesh S.
    J Alzheimers Dis; 2014; 42(2):379-84. PubMed ID: 24898642
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit.
    Giacobini E, Spiegel R, Enz A, Veroff AE, Cutler NR.
    J Neural Transm (Vienna); 2002 Jul; 109(7-8):1053-65. PubMed ID: 12111443
    [Abstract] [Full Text] [Related]

  • 3. Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease.
    Bartorelli L, Giraldi C, Saccardo M, Cammarata S, Bottini G, Fasanaro AM, Trequattrini A, Upgrade Study Group.
    Curr Med Res Opin; 2005 Nov; 21(11):1809-18. PubMed ID: 16307702
    [Abstract] [Full Text] [Related]

  • 4. Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease.
    Blesa R, Bullock R, He Y, Bergman H, Gambina G, Meyer J, Rapatz G, Nagel J, Lane R.
    Pharmacogenet Genomics; 2006 Nov; 16(11):771-4. PubMed ID: 17047484
    [Abstract] [Full Text] [Related]

  • 5. Cholinesterase inhibitors modify the activity of intrinsic cardiac neurons.
    Darvesh S, Arora RC, Martin E, Magee D, Hopkins DA, Armour JA.
    Exp Neurol; 2004 Aug; 188(2):461-70. PubMed ID: 15246845
    [Abstract] [Full Text] [Related]

  • 6. Sensitivity of butyrylcholinesterase knockout mice to (--)-huperzine A and donepezil suggests humans with butyrylcholinesterase deficiency may not tolerate these Alzheimer's disease drugs and indicates butyrylcholinesterase function in neurotransmission.
    Duysen EG, Li B, Darvesh S, Lockridge O.
    Toxicology; 2007 Apr 20; 233(1-3):60-9. PubMed ID: 17194517
    [Abstract] [Full Text] [Related]

  • 7. A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase.
    Greig NH, Utsuki T, Yu Q, Zhu X, Holloway HW, Perry T, Lee B, Ingram DK, Lahiri DK.
    Curr Med Res Opin; 2001 Apr 20; 17(3):159-65. PubMed ID: 11900310
    [Abstract] [Full Text] [Related]

  • 8. Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients.
    Nordberg A, Darreh-Shori T, Peskind E, Soininen H, Mousavi M, Eagle G, Lane R.
    Curr Alzheimer Res; 2009 Feb 20; 6(1):4-14. PubMed ID: 19199870
    [Abstract] [Full Text] [Related]

  • 9. Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition.
    Ballard CG.
    Eur Neurol; 2002 Feb 20; 47(1):64-70. PubMed ID: 11803198
    [Abstract] [Full Text] [Related]

  • 10. Selective inhibitors of butyrylcholinesterase: a valid alternative for therapy of Alzheimer's disease?
    Giacobini E.
    Drugs Aging; 2001 Feb 20; 18(12):891-8. PubMed ID: 11888344
    [Abstract] [Full Text] [Related]

  • 11. The clinical benefits of rivastigmine may reflect its dual inhibitory mode of action: an hypothesis.
    Bullock R.
    Int J Clin Pract; 2002 Apr 20; 56(3):206-14. PubMed ID: 12018828
    [Abstract] [Full Text] [Related]

  • 12. Butyrylcholinesterase: an important new target in Alzheimer's disease therapy.
    Greig NH, Lahiri DK, Sambamurti K.
    Int Psychogeriatr; 2002 Apr 20; 14 Suppl 1():77-91. PubMed ID: 12636181
    [Abstract] [Full Text] [Related]

  • 13. A review on cholinesterase inhibitors for Alzheimer's disease.
    Anand P, Singh B.
    Arch Pharm Res; 2013 Apr 20; 36(4):375-99. PubMed ID: 23435942
    [Abstract] [Full Text] [Related]

  • 14. In vivo butyrylcholinesterase activity is not increased in Alzheimer's disease synapses.
    Kuhl DE, Koeppe RA, Snyder SE, Minoshima S, Frey KA, Kilbourn MR.
    Ann Neurol; 2006 Jan 20; 59(1):13-20. PubMed ID: 16278840
    [Abstract] [Full Text] [Related]

  • 15. Effects of cholinesterase inhibitors on the activities and protein levels of cholinesterases in the cerebrospinal fluid of patients with Alzheimer's disease: a review of recent clinical studies.
    Darreh-Shori T, Soininen H.
    Curr Alzheimer Res; 2010 Feb 20; 7(1):67-73. PubMed ID: 20205672
    [Abstract] [Full Text] [Related]

  • 16. Cholinesterases: new roles in brain function and in Alzheimer's disease.
    Giacobini E.
    Neurochem Res; 2003 Apr 20; 28(3-4):515-22. PubMed ID: 12675140
    [Abstract] [Full Text] [Related]

  • 17. Status of acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease and type 2 diabetes mellitus.
    Mushtaq G, Greig NH, Khan JA, Kamal MA.
    CNS Neurol Disord Drug Targets; 2014 Apr 20; 13(8):1432-9. PubMed ID: 25345511
    [Abstract] [Full Text] [Related]

  • 18. Pharmacodynamics of cholinesterase inhibitors suggests add-on therapy with a low-dose carbamylating inhibitor in patients on long-term treatment with rapidly reversible inhibitors.
    Darreh-Shori T, Hosseini SM, Nordberg A.
    J Alzheimers Dis; 2014 Apr 20; 39(2):423-40. PubMed ID: 24217282
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Switching cholinesterase inhibitors in patients with Alzheimer's disease.
    Emre M.
    Int J Clin Pract Suppl; 2002 Jun 20; (127):64-72. PubMed ID: 12139369
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.